Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ for congenital antithrombin deficiency during pharmacokinetic assessment, high-risk surgery, or delivery
ISRCTN16338908Phase 3Completed
- Sponsor
- Octapharma
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of antithrombin III concentrate in congenital antithrombin deficiency (ATD), sponsored by Octapharma. Primary endpoint: Incidence of thromboembolic events and thromboembolic event equivalents. Started Jun 2022; status: completed.
02
Drugs
antithrombin III concentrate
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on ISRCTN16338908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16338908.